iCo Therapeutics Inc.

93 articles about iCo Therapeutics Inc.

• iCo Therapeutics Inc. Begins Trading On The OTCQX Marketplace

  12/20/2013

• iCo Therapeutics Inc. Announces Program And Intellectual Property Advancements For Oral Amphotericin B

  12/12/2013

• iCo Therapeutics Inc. Grants Options to a Director

  9/6/2013

• iCo Therapeutics Inc. to Present at the Rodman & Renshaw 2013 Annual Global Investment Conference

  9/4/2013

• iCo Therapeutics Inc. Announces Second Quarter 2013 Financial Results

  8/27/2013

• iCo Therapeutics Inc. Announces Completion of Trial Enrollment and Clinical Update for iDEAL Phase 2 Study for the Treatment of Diabetic Macular Edema

  6/18/2013

• iCo Therapeutics Inc. and JDRF Partner to Investigate iCo-007 in Diabetic Macular Edema

  9/26/2011

• iCo Therapeutics Inc. Announces Key iCo-007 Clinical Development Milestone

  8/16/2011

• iCo Therapeutics Inc. Executes Bertilimumab License with Immune Pharmaceuticals in Deal Worth $32 Million

  6/24/2011

• iCo Therapeutics Inc. Secures $10 Million Equity Line Facility

  4/14/2011

• iCo Therapeutics Inc. Completes iCo-007 Phase 2 Clinical Supply Manufacturing

  2/22/2011

• iCo Therapeutics Inc. Extends Investor Relations Engagement with The Trout Group

  12/27/2010

• iCo Therapeutics Inc. Grants License Option for Bertilimumab (iCo-008) Systemic Uses to Immune Pharmaceuticals for $33 Million Plus Royalties

  12/8/2010

• iCo Therapeutics Inc. Reports Third Quarter 2010 Financial Results

  11/29/2010

• iCo Therapeutics Inc. Selected as Canada's Top 10(TM) Competition Winner

  10/13/2010

• iCo Therapeutics Inc. Oral Amphotericin Program Receives FDA Orphan Drug Status

  9/29/2010

• iCo Therapeutics Inc. Appoints Infectious Disease Experts to Scientific Advisory Board

  9/22/2010

• iCo Therapeutics Inc. Announces Second Quarter 2010 Financial Results

  8/30/2010

• iCo Therapeutics Inc. Receives Health Canada Clearance to Conduct Phase II DME Trial With iCo-007

  7/26/2010

• iCo Therapeutics Inc. Enters Into Investor Relations Engagements With The Trout Group and SectorSpeak

  6/1/2010